KOD · Kodiak Sciences Inc. · Executive Compensation
$92.97
+1.62 (+1.77%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, we had cash and cash equivalents of $125.9 million. We have incurred net losses and negative cash flows from operations since inception. We expect to continue to incur operating losses and negative operating cash flows for the foreseeable future and as a result, there is substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$5.74B
Shares
62.85M
Volume · Oct 20
857.92K
Avg daily vol (3M)
1.66M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Victor Perlroth | Chief Executive Officer and Chairman of the Board | $2,725,068 |
| John Borgeson | Executive Vice President, Chief Financial Officer and Secretary | $1,679,701 |
| Jason Ehrlich | M.D., FormerChief Medical Officer and Chief Development Officer | $1,399,888 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Victor Perlroth | Chief Executive Officer and Chairman of the Board | $2,999,421 |
| Jason Ehrlich | M.D., FormerChief Medical Officer and Chief Development Officer | $1,625,797 |
| John Borgeson | Executive Vice President, Chief Financial Officer and Secretary | $1,507,502 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Victor Perlroth | Chief Executive Officer and Chairman of the Board | $113,371,207 |
| Jason Ehrlich | M.D., ChiefMedical Officer and Chief Development Officer | $27,946,551 |
| John Borgeson | Executive Vice President and Chief Financial Officer | $27,871,802 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Victor Perlroth | Chief Executive Officer and Chairman of the Board | $8,942,761 |
| Jason Ehrlich | M.D., ChiefMedical Officer and Chief Development Officer | $3,056,247 |
| John Borgeson | Senior Vice President and Chief Financial Officer | $2,936,607 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Victor Perlroth | Chief Executive Officer and Chairman of the Board | $17,642,007 |
| Jason Ehrlich | M.D., ChiefMedical Officer and Chief Development Officer | $7,716,165 |
| John Borgeson | Senior Vice President and Chief Financial Officer | $6,223,183 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Victor Perlroth | Chief Executive Officer and Chairman of the Board | $5,896,743 |
| Jason Ehrlich | M.D., Ph.D. Chief Medical Officer and Chief Development Officer | $3,745,287 |
| John Borgeson | Senior Vice President and Chief Financial Officer | $2,112,538 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Jason Ehrlich, M.D., Ph.D. | Chief Medical Officer and Chief Development Officer | Resigned | 2023-08-17 |
Leadership
- Victor Perlroth CEO, Board Member
- John Borgeson CFO
- Bassil I. Dahiyat Board Member
- Charles A. Bancroft Board Member
- Continuing Directors Board Member
- Felix J. Baker Board Member
- Richard S. Levy Board Member
- Robert A. Profusek Board Member
- Taiyin Yang Board Member
Key facts
CIK
1468748
CUSIP
50015M109
13F (30d)
13 filings
13 filers
Visit website
Investor relations